ORMP

Oramed Pharmaceuticals Inc. [ORMP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ORMP Stock Summary

Top 10 Correlated ETFs

ORMP


Top 10 Correlated Stocks

ORMP


In the News

10:46 16 Apr 2024 ORMP

Best Penny Stocks To Buy Today? 4 To Watch Under $5

Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today?

11:50 16 Apr 2024 ORMP

Why Oramed Pharmaceuticals Stock Is Crashing Today

The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.

10:44 16 Apr 2024 ORMP

Why Is Oramed (ORMP) Stock Down 75% Today?

Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-0801 in patients with Type 2 Diabetes at 26 weeks against those taking a placebo.

08:02 16 Apr 2024 ORMP

Oramed's oral insulin pill fails; stock is down 72%

Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed's treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes.

03:49 16 Apr 2024 ORMP

Oramed: NASH Biotech Play With Added Bonus

Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of concept. Results from the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes are expected in January of 2023.

05:52 16 Apr 2024 ORMP

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively.

02:22 16 Apr 2024 ORMP

Why Oramed Pharmaceuticals Stock Is On Fire Today

The biotech's stock has been ripping higher of late.

05:56 16 Apr 2024 ORMP

Why Oramed Pharmaceuticals Stock Rocketed Higher Today

A reassuring letter to shareholders has the biotech's stock jumping today.

04:02 16 Apr 2024 ORMP

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.

06:14 16 Apr 2024 ORMP

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug maker's stock slipped 0.1% in premarket trading.

ORMP Financial details

Company Rating
Neutral
Market Cap
102.11M
Income
-14.76M
Revenue
2.02M
Book val./share
3.69
Cash/share
4.33
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-6.63
Forward P/E
-2.24
PEG
1.27
P/S
48.3
P/B
0.66
P/C
0.56
P/FCF
-5.58
Quick Ratio
2.24
Current Ratio
2.25
Debt / Equity
0.51
LT Debt / Equity
0
-
-
EPS (TTM)
-0.37
EPS next Y
-1.08
EPS next Q
-0.02
EPS this Y
24.36%
EPS next Y
188.54%
EPS next 5Y
119.08%
EPS last 5Y
2.44%
Revenue last 5Y
1.99%
Revenue Q/Q
-
EPS Q/Q
168.35%
-
-
-
-
SMA20
-
SMA50
-
SMA100
50%
Inst Own
5.13%
Inst Trans
0.94%
ROA
-6%
ROE
-10%
ROC
-0.14%
Gross Margin
100%
Oper. Margin
-1070%
Profit Margin
-730%
Payout
-
Shs Outstand
40.52M
Shs Float
34.73M
-
-
-
-
Target Price
-
52W Range
1.67-5.25
52W High
-51.6%
52W Low
+142%
RSI
37
Rel Volume
0.74
Avg Volume
175.79K
Volume
130.87K
Perf Week
-7.28%
Perf Month
-25.54%
Perf Quarter
25.39%
Perf Half Y
11.01%
-
-
-
-
Beta
1.817
-
-
Volatility
0.11%, 0.17%
Prev Close
-3.97%
Price
2.42
Change
-6.56%

ORMP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-08-312019-08-312020-08-312021-08-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.160.150.130.090.07
Net income per share
-0.86-0.82-0.56-0.78-0.97
Operating cash flow per share
-0.98-0.74-0.61-0.74-0.72
Free cash flow per share
-0.99-0.74-0.61-0.76-0.73
Cash per share
2.051.851.943.313.99
Book value per share
2.091.111.64.073.89
Tangible book value per share
2.091.111.64.093.88
Share holders equity per share
2.091.111.64.073.89
Interest debt per share
-0.53-0.3300.02-0.05
Market cap
73.67M57.95M71.66M560.27M469.14M
Enterprise value
68.67M54.62M52.44M483.56M429.57M
P/E ratio
-5.79-4.04-6.23-25.19-12.42
Price to sales ratio
30.0821.4426.44207.28173.56
POCF ratio
-5.03-4.48-5.76-26.45-16.8
PFCF ratio
-5.02-4.47-5.72-25.99-16.51
P/B Ratio
2.372.992.184.843.09
PTB ratio
2.372.992.184.843.09
EV to sales
28.0420.2119.35178.9158.92
Enterprise value over EBITDA
-5.09-3.85-4.64-19.31-11.62
EV to operating cash flow
-4.69-4.22-4.22-22.83-15.39
EV to free cash flow
-4.68-4.22-4.19-22.43-15.12
Earnings yield
-0.17-0.25-0.16-0.04-0.08
Free cash flow yield
-0.2-0.22-0.17-0.04-0.06
Debt to equity
-0.25-0.29000.01
Debt to assets
-0.16-0.16000.01
Net debt to EBITDA
0.370.231.73.061.07
Current ratio
6.826.288.9314.2727.34
Interest coverage
0116.120013.84
Income quality
1.150.91.080.920.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.671.381.562.25.11
Research and developement to revenue
4.8953.787.7710.23
Intangibles to total assets
00000
Capex to operating cash flow
000.010.020.02
Capex to revenue
0-0.01-0.03-0.14-0.18
Capex to depreciation
-0.83-1.88-11.71-4.87-8.55
Stock based compensation to revenue
0.630.30.4314.26
Graham number
6.344.534.498.459.21
ROIC
-0.54-1.09-0.36-0.18-0.27
Return on tangible assets
-0.27-0.41-0.26-0.17-0.23
Graham Net
0.950.971.372.93.72
Working capital
26.48M28.02M35.98M88.66M151.36M
Tangible asset value
31.11M19.39M32.88M116.52M151.16M
Net current asset value
14.75M18.05M28.76M83.86M146.62M
Invested capital
-0.25-0.29000.01
Average receivables
00000
Average payables
853K1.24M965.5K1.6M2.39M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
4.82K5.42K2.41K00
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.080.070.1500
Inventory turnover
00000
ROE
-0.41-0.74-0.35-0.19-0.25
Capex per share
000-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.020.020.020.020
Net income per share
-0.19-0.22-0.04-0.03-0.08
Operating cash flow per share
-0.06-0.21-0.14-0.07-0.02
Free cash flow per share
-0.06-0.21-0.14-0.07-0.02
Cash per share
4.083.993.843.734.33
Book value per share
3.933.893.773.773.69
Tangible book value per share
3.923.883.753.753.66
Share holders equity per share
3.933.893.773.773.69
Interest debt per share
0.050.06-0.020.021.9
Market cap
253.37M469.14M87.29M144.01M105.56M
Enterprise value
221.07M429.57M63.99M137.96M176.1M
P/E ratio
-8.73-13.73-12.14-30.15-8.19
Price to sales ratio
371.51688.9131.07213.660
POCF ratio
-113.06-58.19-15.73-54.67-152.11
PFCF ratio
-107.27-56.05-15.19-54.26-145.4
P/B Ratio
1.653.090.580.950.71
PTB ratio
1.653.090.580.950.71
EV to sales
324.15630.896.08204.70
Enterprise value over EBITDA
-27.05-63.27-12.38-36.9-73.25
EV to operating cash flow
-98.65-53.28-11.53-52.38-253.74
EV to free cash flow
-93.6-51.32-11.13-51.98-242.56
Earnings yield
-0.03-0.02-0.02-0.01-0.03
Free cash flow yield
-0.01-0.02-0.07-0.02-0.01
Debt to equity
0.010.010.0100.51
Debt to assets
0.010.010.0100.33
Net debt to EBITDA
3.955.834.511.62-29.34
Current ratio
24.5527.3431.21141.492.25
Interest coverage
-7.9-5.963.260-3.5
Income quality
0.310.921.542.010.21
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
4.4941.93.640
Research and developement to revenue
7.8410.696.652.70
Intangibles to total assets
00000
Capex to operating cash flow
0.050.040.040.010.05
Capex to revenue
-0.18-0.45-0.3-0.030
Capex to depreciation
-8.07-18.12-5.38-0.38-0.59
Stock based compensation to revenue
4.473.740.262.70
Graham number
4.054.381.951.592.57
ROIC
-0.05-0.06-0.02-0.02-0.01
Return on tangible assets
-0.04-0.05-0.01-0.01-0.01
Graham Net
3.793.723.63.592.28
Working capital
153.65M151.36M150.19M149.9M97.53M
Tangible asset value
153.15M151.16M150.15M150.66M148.23M
Net current asset value
148.88M146.62M145.53M145.31M93.04M
Invested capital
0.010.010.0100.51
Average receivables
00000
Average payables
3.84M3.19M3.12M2.44M1.69M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.05-0.06-0.01-0.01-0.02
Capex per share
0-0.01000

ORMP Frequently Asked Questions

What is Oramed Pharmaceuticals Inc. stock symbol ?

Oramed Pharmaceuticals Inc. is a US stock , located in New york of Ny and trading under the symbol ORMP

What is Oramed Pharmaceuticals Inc. stock quote today ?

Oramed Pharmaceuticals Inc. stock price is $2.42 today.

Is Oramed Pharmaceuticals Inc. stock public?

Yes, Oramed Pharmaceuticals Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap